{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:25:44Z","timestamp":1790713544942,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI136680"],"award-info":[{"award-number":["R01 AI136680"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI146017"],"award-info":[{"award-number":["R01 AI146017"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 AI150472"],"award-info":[{"award-number":["U54 AI150472"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P41 GM103311"],"award-info":[{"award-number":["P41 GM103311"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.tips.2020.06.003","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:14:08Z","timestamp":1593735248000},"page":"611-626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Structural Biology of HIV Integrase Strand Transfer Inhibitors"],"prefix":"10.1016","volume":"41","author":[{"given":"Ilona K.","family":"J\u00f3\u017awik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario O.","family":"Passos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8124-7472","authenticated-orcid":false,"given":"Dmitry","family":"Lyumkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2020.06.003_bb0005","first-page":"1","article-title":"HIV infection","volume":"1","author":"Deeks","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.tips.2020.06.003_bb0010","doi-asserted-by":"crossref","first-page":"a007161","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.tips.2020.06.003_bb0015","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41586-019-1841-8","article-title":"Why and where an HIV cure is needed and how it might be achieved","volume":"576","author":"Ndung\u2019u","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.tips.2020.06.003_bb0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev-med-011514-023043","article-title":"Progress toward HIV eradication: case reports, current efforts, and the challenges associated with cure","volume":"67","author":"Martin","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.tips.2020.06.003_bb0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.sbi.2019.11.011","article-title":"Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance","volume":"61","author":"Ruiz","year":"2020","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.tips.2020.06.003_bb0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.tim.2016.03.010","article-title":"Improving viral protease inhibitors to counter drug resistance","volume":"24","author":"Kurt Yilmaz","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.tips.2020.06.003_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.201800159","article-title":"HIV-1 entry inhibitors: a review of experimental and computational studies","volume":"15","author":"Mostashari Rad","year":"2018","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.tips.2020.06.003_bb0040","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/phar.2246","article-title":"Integrase inhibitors: after 10 years of experience, is the best yet to come?","volume":"39","author":"Brooks","year":"2019","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.tips.2020.06.003_bb0045","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1021\/jm800245z","article-title":"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection","volume":"51","author":"Summa","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0050","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2020.06.003_bb0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11584570-000000000-00000","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir","volume":"50","author":"Ramanathan","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.tips.2020.06.003_bb0060","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1128\/AAC.00842-09","article-title":"Pharmacokinetics and safety of S\/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers","volume":"54","author":"Min","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2020.06.003_bb0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12977-018-0420-7","article-title":"Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants","volume":"15","author":"Smith","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.tips.2020.06.003_bb0070","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12688\/f1000research.15995.2","article-title":"Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: systematic review and meta-analysis","volume":"7","author":"Wandeler","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.tips.2020.06.003_bb0075","doi-asserted-by":"crossref","first-page":"104717","DOI":"10.1016\/j.antiviral.2020.104717","article-title":"Failure to Biktarvy\u00ae and development of resistance mutations in an antiretroviral-experienced patient","volume":"23","author":"Lozano","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.tips.2020.06.003_bb0080","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.tips.2020.06.003_bb0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.tips.2020.06.003_bb0090","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature08784","article-title":"Retroviral intasome assembly and inhibition of DNA strand transfer","volume":"464","author":"Hare","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.tips.2020.06.003_bb0095","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nature09517","article-title":"The mechanism of retroviral integration from X-ray structures of its key intermediates","volume":"468","author":"Maertens","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.tips.2020.06.003_bb0100","doi-asserted-by":"crossref","first-page":"20057","DOI":"10.1073\/pnas.1010246107","article-title":"Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance","volume":"107","author":"Hare","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2020.06.003_bb0105","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.aay4919","article-title":"Structural basis of second-generation HIV integrase inhibitor action and viral resistance","volume":"367","author":"Cook","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.tips.2020.06.003_bb0110","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1126\/science.aay8015","article-title":"Structural basis for strand transfer inhibitor binding to HIV intasomes","volume":"367","author":"Passos","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.tips.2020.06.003_bb0115","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1074\/jbc.REV118.005602","article-title":"Challenges and opportunities in cryo-EM single-particle analysis","volume":"294","author":"Lyumkis","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1017\/S0033583516000068","article-title":"Single particle electron cryomicroscopy: trends, issues and future perspective","volume":"49","author":"Vinothkumar","year":"2016","journal-title":"Q. Rev. Biophys."},{"key":"10.1016\/j.tips.2020.06.003_bb0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nmeth.3694","article-title":"The development of cryo-EM into a mainstream structural biology technique","volume":"13","author":"Nogales","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.tips.2020.06.003_bb0130","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1073\/pnas.93.18.9742","article-title":"Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules","volume":"93","author":"Farnet","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2020.06.003_bb0135","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1128\/jvi.71.9.7005-7011.1997","article-title":"Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase","volume":"71","author":"Hazuda","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2020.06.003_bb0140","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1101\/gad.3.4.469","article-title":"A nucleoprotein complex mediates the integration of retroviral DNA","volume":"3","author":"Bowerman","year":"1989","journal-title":"Genes Dev."},{"key":"10.1016\/j.tips.2020.06.003_bb0145","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1128\/jvi.71.7.5382-5390.1997","article-title":"Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition","volume":"71","author":"Miller","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2020.06.003_bb0150","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1093\/emboj\/16.24.7511","article-title":"A large nucleoprotein assembly at the ends of the viral DNA mediates retroviral DNA integration","volume":"16","author":"Wei","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2020.06.003_bb0155","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0092-8674(91)90297-C","article-title":"HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer","volume":"67","author":"Engelman","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.tips.2020.06.003_bb0160","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/0092-8674(90)90126-Y","article-title":"The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro","volume":"62","author":"Craigie","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.tips.2020.06.003_bb0165","first-page":"17","article-title":"Discovery and analysis of inhibitors of the human immunodeficiency integrase","volume":"15","author":"Hazuda","year":"1997","journal-title":"Drug Des. Discov."},{"key":"10.1016\/j.tips.2020.06.003_bb0170","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1021\/jm9801760","article-title":"Salicylhydrazine-containing inhibitors of HIV-1 integrase: Implication for a selective chelation in the integrase active site","volume":"41","author":"Neamati","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0175","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrd1660","article-title":"Integrase inhibitors to treat HIV\/AIDS","volume":"4","author":"Pommier","year":"2005","journal-title":"Drug Discov."},{"key":"10.1016\/j.tips.2020.06.003_bb0180","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells","volume":"287","author":"Hazuda","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.tips.2020.06.003_bb0185","doi-asserted-by":"crossref","first-page":"11244","DOI":"10.1073\/pnas.200139397","article-title":"HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase","volume":"97","author":"Espeseth","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.tips.2020.06.003_bb0190","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1021\/jm0600139","article-title":"Novel HIV-1 integrase inhibitors derived from quinolone antibiotics","volume":"49","author":"Sato","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0195","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1128\/AAC.00157-11","article-title":"Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes","volume":"55","author":"Hightower","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2020.06.003_bb0200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/AAC.01733-09","article-title":"Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates","volume":"55","author":"Van Wesenbeeck","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2020.06.003_bb0205","doi-asserted-by":"crossref","first-page":"78","DOI":"10.32607\/20758251-2015-7-1-78-86","article-title":"Influence of drug resistance mutations on the activity of HIV-1 subtypes A and B integrases: a comparative study","volume":"7","author":"Shadrina","year":"2015","journal-title":"Acta Nat."},{"key":"10.1016\/j.tips.2020.06.003_bb0210","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/nar\/gkn1050","article-title":"The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation","volume":"37","author":"Delelis","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2020.06.003_bb0215","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50524","article-title":"Epistasis and entrenchment of drug resistance in HIV-1 subtype B","volume":"8","author":"Biswas","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.tips.2020.06.003_bb0220","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s13318-018-0526-2","article-title":"Pharmacokinetics and pharmacodynamics of cabotegravir, a long-acting HIV integrase strand transfer inhibitor","volume":"3","author":"Cattaneo","year":"2019","journal-title":"Eur. J Drug Metab. Pharmacokinet"},{"key":"10.1016\/j.tips.2020.06.003_bb0225","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1124\/mol.111.073189","article-title":"Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S\/GSK1349572)","volume":"80","author":"Hare","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2020.06.003_bb0230","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1016\/j.bmcl.2009.03.122","article-title":"Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-ones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones","volume":"19","author":"Zhao","year":"2009","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.tips.2020.06.003_bb0235","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0000000000000453","article-title":"Dolutegravir resistance mutations: lessons from monotherapy studies","volume":"31","author":"Blanco","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.tips.2020.06.003_bb0240","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02533-18","article-title":"Resistance analysis of bictegravir-emtricitabine-tenofovir alafenamide in HIV-1 treatment-naive patients through 48 weeks","volume":"63","author":"Acosta","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2020.06.003_bb0245","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAI.0000000000001306","article-title":"Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults","volume":"75","author":"Gallant","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tips.2020.06.003_bb0250","doi-asserted-by":"crossref","first-page":"10245","DOI":"10.1128\/JVI.00894-09","article-title":"Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes","volume":"83","author":"Quercia","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2020.06.003_bb0255","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0b013e3181e9a87a","article-title":"Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness","volume":"55","author":"Hu","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tips.2020.06.003_bb0260","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy221","article-title":"Rapid development of high-level resistance to dolutegravir with emergence of T97A mutation in 2 treatment-experienced individuals with baseline partial sensitivity to dolutegravir","volume":"5","author":"George","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.tips.2020.06.003_bb0265","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.1128\/JVI.01164-10","article-title":"Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor","volume":"84","author":"Bar-Magen","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2020.06.003_bb0270","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ardp.201500237","article-title":"1,8-naphthyridine derivatives: a review of multiple biological activities","volume":"348","author":"Madaan","year":"2015","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.tips.2020.06.003_bb0275","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2174\/1573406412666161228112127","article-title":"Naphthyridines with antiviral activity \u2013 a review","volume":"13","author":"Singh","year":"2017","journal-title":"Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0280","doi-asserted-by":"crossref","first-page":"11233","DOI":"10.1073\/pnas.0402357101","article-title":"A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase","volume":"101","author":"Hazuda","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2020.06.003_bb0285","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1016\/j.bmcl.2010.08.135","article-title":"Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold","volume":"20","author":"Williams","year":"2010","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.tips.2020.06.003_bb0290","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1021\/jm401902n","article-title":"Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants","volume":"57","author":"Zhao","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0295","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1021\/jm5001908","article-title":"4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1","volume":"57","author":"Zhao","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0300","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1021\/acschembio.5b00948","article-title":"HIV-1 integrase strand transfer inhibitors with reduced susceptibility to drug resistant mutant integrases","volume":"11","author":"Zhao","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.tips.2020.06.003_bb0305","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1021\/acs.jmedchem.7b00596","article-title":"Structure-guided optimization of HIV integrase strand transfer inhibitors","volume":"60","author":"Zhao","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0310","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01035-18","article-title":"HIV-1 integrase inhibitors that are broadly effective against drug-resistant mutants","volume":"62","author":"Smith","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2020.06.003_bb0315","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1021\/jm300337q","article-title":"Ligand binding stepwise disrupts water network in thrombin: Enthalpic and entropic changes reveal classical hydrophobic effect","volume":"55","author":"Biela","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0320","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/anie.201208561","article-title":"Dissecting the hydrophobic effect on the molecular level: The role of water, enthalpy, and entropy in ligand binding to thermolysin","volume":"52","author":"Biela","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.tips.2020.06.003_bb0325","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1021\/acs.jmedchem.7b00490","article-title":"Paying the price of desolvation in solvent-exposed protein pockets: Impact of distal solubilizing groups on affinity and binding thermodynamics in a series of thermolysin inhibitors","volume":"60","author":"Cramer","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0330","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cmdc.201400013","article-title":"Methyl, ethyl, propyl, butyl: futile but not for water, as the correlation of structure and thermodynamic signature shows in a congeneric series of thermolysin inhibitors","volume":"9","author":"Krimmer","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.tips.2020.06.003_bb0335","doi-asserted-by":"crossref","first-page":"126784","DOI":"10.1016\/j.bmcl.2019.126784","article-title":"Heterocycle amide isosteres: an approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors","volume":"30","author":"Peese","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2020.06.003_bb0340","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1021\/acs.jmedchem.6b00040","article-title":"3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides potently inhibit HIV-1 integrase and RNase H","volume":"59","author":"Wu","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0345","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejmech.2016.03.083","article-title":"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: influence of the alkylcarboxamide substitution of position 4","volume":"117","author":"Billamboz","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0350","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejmech.2016.03.038","article-title":"The design of 8-hydroxyquinoline tetracyclic lactams as HIV-1 integrase strand transfer inhibitors","volume":"117","author":"Velthuisen","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0355","series-title":"Antiviral Drugs","first-page":"163","article-title":"Discovery of MK-0536: a potential second-generation HIV-1 integrase strand transfer inhibitor with a high genetic barrier to mutation","author":"Egbertson","year":"2011"},{"key":"10.1016\/j.tips.2020.06.003_bb0360","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1021\/acs.jmedchem.5b01037","article-title":"Discovery of 2-pyridinone aminals: a prodrug strategy to advance a second generation of HIV-1 integrase strand transfer inhibitors","volume":"58","author":"Raheem","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0365","doi-asserted-by":"crossref","first-page":"115541","DOI":"10.1016\/j.bmc.2020.115541","article-title":"Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors","author":"Patel","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0370","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/13543776.2017.1360283","article-title":"Identification of spirocyclic or phosphate substituted quinolizine derivatives as novel HIV-1 integrase inhibitors: a patent evaluation of WO2016094197A1, WO2016094198A1 and WO2016154527A1","volume":"27","author":"Cheng","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.tips.2020.06.003_bb0375","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bmcl.2014.11.060","article-title":"Synthesis and evaluation of C2-carbon-linked heterocyclic-5-hydroxy-6-oxo-dihydropyrimidine-4-carboxamides as HIV-1 integrase inhibitors","volume":"25","author":"Naidu","year":"2015","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.tips.2020.06.003_bb0380","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.bmcl.2016.01.028","article-title":"Pyridoxine hydroxamic acids as novel HIV-integrase inhibitors","volume":"26","author":"Stranix","year":"2016","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.tips.2020.06.003_bb0385","doi-asserted-by":"crossref","first-page":"112064","DOI":"10.1016\/j.ejmech.2020.112064","article-title":"Synthesis, biological evaluation and in silico modeling of novel integrase strand transfer inhibitors (INSTIs)","volume":"189","author":"Ivashchenko","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2020.06.003_bb0390","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM199604183341602","article-title":"Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine","volume":"334","author":"Collier","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2020.06.003_bb0395","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJM199508173330710","article-title":"Time to hit HIV, early and hard","volume":"333","author":"Ho","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2020.06.003_bb0400","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2020.06.003_bb0405","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","article-title":"Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection","volume":"373","author":"Ho","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.tips.2020.06.003_bb0410","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.271.5255.1582","article-title":"HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time","volume":"271","author":"Perelson","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.tips.2020.06.003_bb0415","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2020.06.003_bb0420","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12977-018-0395-4","article-title":"HIV evolution and diversity in ART-treated patients","volume":"15","author":"van Zyl","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.tips.2020.06.003_bb0425","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cbpa.2013.04.010","article-title":"Allosteric inhibition of HIV-1 integrase activity","volume":"3","author":"Engelman","year":"2013","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.tips.2020.06.003_bb0430","doi-asserted-by":"crossref","first-page":"12730","DOI":"10.1021\/acs.chemrev.6b00125","article-title":"Retroviral DNA Integration","volume":"116","author":"Lesbats","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.tips.2020.06.003_bb0435","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1038\/emboj.2012.118","article-title":"3\u2032-processing and strand transfer catalysed by retroviral integrase in crystallo","volume":"31","author":"Hare","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2020.06.003_bb0440","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature16955","article-title":"Cryo-EM reveals a novel octameric integrase structure for betaretroviral intasome function","volume":"530","author":"Ballandras-Colas","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.tips.2020.06.003_bb0445","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature16950","article-title":"Crystal structure of the Rous sarcoma virus intasome","volume":"530","author":"Yin","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.tips.2020.06.003_bb0450","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1126\/science.aah7002","article-title":"A supramolecular assembly mediates lentiviral DNA integration","volume":"355","author":"Ballandras-Colas","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.tips.2020.06.003_bb0455","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.aah5163","article-title":"Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome","volume":"355","author":"Passos","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.tips.2020.06.003_bb0460","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.sbi.2017.04.005","article-title":"Retroviral intasomes arising","volume":"47","author":"Engelman","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.tips.2020.06.003_bb0465","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1021\/cb400468c","article-title":"Testing the substrate-envelope hypothesis with designed pairs of compounds","volume":"8","author":"Shen","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.tips.2020.06.003_bb0470","first-page":"1333","article-title":"Combating susceptibility to drug resistance: Lessons from HIV-1 protease","volume":"11","author":"King","year":"2004","journal-title":"Chem. Biol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614720301395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614720301395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:16:21Z","timestamp":1778670981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614720301395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":94,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0165614720301395"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2020.06.003","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural Biology of HIV Integrase Strand Transfer Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2020.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}